```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1790 Introduced in House (IH)]

<DOC>

118th CONGRESS
  1st Session
                                H. R. 1790

 To direct the Secretary of Health and Human Services to evaluate the 
extent to which the substitution of interchangeable biological products 
    is impacted by differences between the system for determining a 
 biological product to be interchangeable and the system for assigning 
   therapeutic equivalence ratings to drugs, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 24, 2023

   Mrs. Miller-Meeks (for herself, Ms. Barragan, Mr. Murphy, and Ms. 
   Kuster) introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

 
 To direct the Secretary of Health and Human Services to evaluate the 
extent to which the substitution of interchangeable biological products 
    is impacted by differences between the system for determining a 
 biological product to be interchangeable and the system for assigning 
   therapeutic equivalence ratings to drugs, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Biologics Competition Act of 2023''.

SEC. 2. STUDY ON THE SUBSTITUTION OF INTERCHANGEABLE BIOLOGICAL 
              PRODUCTS.

    Not later than 12 months after the date of enactment of this Act, 
the Secretary of Health and Human Services shall--
            (1) complete a study to evaluate the extent to which the 
        substitution of interchangeable biological products licensed 
        under section 351 of the Public Health Service Act (42 U.S.C. 
        262) may be impacted by differences between the system for 
        determining a biological product to be interchangeable under 
        section 351(k)(4) of such Act (42 U.S.C. 262(k)(4)) and the 
        system for assigning therapeutic equivalence ratings to drugs 
        approved under section 505 of the Federal Food, Drug, and 
        Cosmetic Act (21 U.S.C. 355);
            (2) submit a report to the Congress on the results of the 
        study under paragraph (1); and
            (3) update the list published under section 351(k)(9)(A) of 
        the Public Health Service Act (42 U.S.C. 262(k)(9)(A)) 
        (commonly referred to as the ``Purple Book'') to implement such 
        changes as the Secretary deems necessary to harmonize the 
        approach for communicating the substitutability of 
        interchangeable biological products with the approach for 
        communicating therapeutic equivalence ratings assigned to 
        drugs, with the goals of--
                    (A) minimizing any impediments to the substitution 
                of interchangeable biological products; and
                    (B) maintaining the distinct pathways by which 
                biological products are licensed under section 351 of 
                the Public Health Service Act (42 U.S.C. 262) and drugs 
                are approved under section 505 of the Federal Food, 
                Drug, and Cosmetic Act (21 U.S.C. 355).
                                 <all>
```